Kimberly Schaff Kiehl: Final Debarment Order
FDA issued a 10-year debarment order against Kimberly Schaff Kiehl, prohibiting her from importing or offering to import any drug. This affects med-spas that may have used her services or products, requiring immediate review of supply chains and personnel.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Med-spas and aesthetics clinics that have engaged Kimberly Schaff Kiehl as a supplier, consultant, or employee involved in drug importation. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; ongoing compliance required.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Kimberly Schaff Kiehl is now debarred from importing drugs for 10 years, making any drugs she imported or offered for import adulterated under the FD&C Act.
Who it affects
Med-spas and aesthetics clinics that have engaged Kimberly Schaff Kiehl as a supplier, consultant, or employee involved in drug importation.
What you must do
Identify any business relationship with Kimberly Schaff Kiehl and cease using any drugs she imported. Review and verify all drug suppliers and importers are not debarred.
Deadline
Immediately; ongoing compliance required.
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication